Lite Strategy Inc

Lite Strategy Inc a clinicalstage pharmaceutical company focuses on the development of various therapies for the treatment of cancer It develops ME344 an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer colorectal cancer and solid tumors It also engages in digital asset treasury management The company was formerly known as MEI Pharma Inc and changed its name to Lite Strategy Inc in September 2025 Lite Strategy Inc was incorporated in 2000 and is based in San Diego California